Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2020-03-25 Board/Management Inform…
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment of an outside director. The title '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' translates to 'Report on the Appointment, Dismissal, or Resignation of Outside Directors'. This falls under the category of Board/Management Information as it pertains to changes in the company's board composition.
2020-03-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend declarations, election of directors and audit committee members, and other resolutions passed during the meeting held on 2020-03-24. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2020-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Dongkoo Bio & Pharma. It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement regarding the submission of the audit report to the exchange, rather than the full annual report (10-K) or a standalone audit report document. Given the short length and the nature of the disclosure as a regulatory filing requirement, it fits the RNS (Regulatory Filings) category. FY 2019
2020-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from Dongkoo Bio & Pharma regarding a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard requirement in the Korean stock market (KRX) for listed companies to announce preliminary financial results before the final audit is completed. It provides key financial metrics and the reasons for the variance, fitting the definition of an Earnings Release (ER).
2020-03-09 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongkoo Bio & Pharma regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, the payment date, and the approval process via the upcoming general meeting of shareholders. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-03-09 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Dongkoo Bio & Pharma. It contains the meeting agenda, details on voting procedures (including electronic voting), and extensive management information regarding business performance, market share, and future strategy. This type of document is a standard proxy statement/information circular provided to shareholders to inform them of upcoming votes and company status, which falls under the 'Proxy Solicitation & Information Statement' category.
2020-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.